Inflectra vs. Entyvio

• Are Entyvio and Inflectra the Same Thing?
• What Are Possible Side Effects of Inflectra?
• What Are Possible Side Effects of Entyvio?
• What Is Inflectra?
• What Is Entyvio?
• What Drugs Interact with Inflectra?
• What Drugs Interact with Entyvio?
• How Should Inflectra Be Taken?
• How Should Entyvio Be Taken?

Inflectra (infliximab-dyyb) for Injection and Entyvio (vedolizumab) are used to reduce signs and symptoms of Crohn's disease, pediatric Crohn's disease, and ulcerative colitis.

Inflectra is also used to reduce signs and symptoms of rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Inflectra and Entyvio belong to different drug classes. Inflectra is a tumor necrosis factor (TNF) blocker and Entyvio is an IgG1 monoclonal antibody.

Side effects of Inflectra and Entyvio that are similar include upper respiratory infections, sinus infections, runny or stuffy nose, bronchitis, sore throat, cough, headache, nausea, rash, itching, fatigue, fever, and joint pain.

Side effects of Inflectra that are different from Entyvio include infusion-related reactions, abdominal pain, indigestion, diarrhea, pain, oral thrush, urinary tract infection (UTI), and high blood pressure (hypertension).

Side effects of Entyvio that are different from Inflectra include common cold symptoms (sinus pain, sneezing), infections of the nose and throat, tiredness, flu symptoms, back pain, and pain in your arms or legs.

Both Inflectra and Entyvio may interact with "live" vaccines.

Inflectra may also interact with anakinra, abatacept, tocilizumab, other biological therapeutics used to treat the same conditions, warfarin, cyclosporine, and theophylline.

Entyvio may also interact with natalizumab and TNF blockers.

Common side effects of Inflectra include:

• upper respiratory infections
• sinus infections
• runny or stuffy nose
• sore throat
• cough
• bronchitis
• infusion-related reactions
• headache
• abdominal pain
• nausea
• diarrhea
• indigestion
• rash
• itching
• fatigue
• pain
• fever
• oral thrush
• joint pain
• urinary tract infection, and
• high blood pressure (hypertension)

Common side effects of Entyvio include:

• common cold symptoms (runny or stuffy nose, sinus pain, sneezing, cough),
• headache,
• joint pain,
• nausea,
• fever,
• infections of the nose and throat,
• tiredness,
• fatigue,
• upper respiratory tract infection,
• bronchitis,
• flu symptoms,
• back pain,
• rash,
• itching,
• sinus infection,
• sore throat, and
• pain in your arms or legs.

Inflectra (infliximab-dyyb) for Injection is a tumor necrosis factor (TNF) blocker indicated for reducing signs and symptoms of Crohn's disease, pediatric Crohn's disease, ulcerative colitis, rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Entyvio (vedolizumab) is an IgG1 monoclonal antibody used to treat moderate to severe active ulcerative colitis (UC) and moderate to severe active Crohn's disease (CD).

Inflectra may interact with anakinra, abatacept, tocilizumab, other biological therapeutics used to treat the same conditions, warfarin, cyclosporine, theophylline, or "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. During pregnancy, Inflectra should be administered only if prescribed. It is unknown if it would affect a fetus. It is unknown if Inflectra passes into breast milk. Because of the potential for unwanted effects on a nursing infant, breastfeeding while using Inflectra is not recommended.

Entyvio may interact with natalizumab, TNF blockers, and "live" vaccines. Tell your doctor all medications and supplements you use and all vaccines you recently received. Tell your doctor if you are pregnant or plan to become pregnant before using Entyvio. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.

Inflectra is administered by intravenous infusion and the dose is based on the patient's weight and the condition being treated.

The recommended dosage of Entyvio in adults with ulcerative colitis or Crohn's disease is 300 mg administered by intravenous infusion at zero, two, and six weeks, and then every eight weeks thereafter.